Meiji Seika Pharma Co., Ltd.
Clinical trials sponsored by Meiji Seika Pharma Co., Ltd., explained in plain language.
Pharmaceutical arm of Meiji Holdings, making antibiotics and CNS drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New antibiotic cocktail takes on superbugs in phase 3 trial
Disease control CompletedThis study tested two new antibiotic combinations (cefepime/nacubactam and aztreonam/nacubactam) against the best available treatments for adults with serious infections like urinary tract infections, pneumonia, and abdominal infections caused by carbapenem-resistant bacteria. Th…
Phase: PHASE3 • Sponsor: Meiji Seika Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New antibiotic cocktails take on tough UTIs and kidney infections
Disease control CompletedThis phase 3 trial tested two new antibiotic combinations—cefepime/nacubactam and aztreonam/nacubactam—against a standard antibiotic (imipenem/cilastatin) in 614 adults with complicated urinary tract infections or acute kidney infections. The goal was to see if the new combos are…
Phase: PHASE3 • Sponsor: Meiji Seika Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC